Related by context. All words. (Click for frequent words.) 78 chemotherapies 77 chemotherapeutics 76 chemotherapeutic drugs 74 anticancer agents 72 cytotoxic agents 71 taxanes 71 chemotherapeutic drug 71 doxorubicin 71 chemotherapeutic 70 anticancer therapy 70 cisplatin 69 EGFR inhibitors 69 tyrosine kinase inhibitors 69 chemotherapeutic agent 69 imatinib Gleevec 69 chemotherapy regimens 69 cytotoxic chemotherapy 68 5 FU 68 cytotoxic 68 anticancer drugs 68 chemotherapeutic regimens 68 proteasome inhibitors 68 erlotinib Tarceva ® 67 solid tumors 67 PARP inhibitors 67 vinca alkaloids 67 idarubicin 67 bortezomib 66 anticancer therapies 66 tyrosine kinase inhibitor 66 nucleoside analogs 66 mycophenolate mofetil 66 EGFR tyrosine kinase inhibitors 66 topotecan 66 cyclophosphamide 66 TKIs 66 gemcitabine 66 MEK inhibitors 66 TACE 66 Cisplatin 66 molecularly targeted 66 etoposide 66 relapsed ovarian cancer 65 calcineurin inhibitors 65 cytotoxicity 65 sorafenib Nexavar 65 standard chemotherapy regimens 65 mTOR inhibitors 65 xenograft models 65 interferons 65 vorinostat 65 5 fluorouracil 65 anthracyclines 65 bevacizumab Avastin 65 immunosuppressive agents 65 5FU 65 anti angiogenic agents 65 bevacizumab Avastin ® 64 PXD# 64 imatinib 64 MMP inhibitors 64 trastuzumab 64 NNRTIs 64 VEGF inhibitors 64 HDAC inhibitors 64 pertuzumab 64 imetelstat 64 immunomodulator 64 tyrosine kinase inhibitors TKIs 64 kinase inhibitors 64 multitargeted 64 Fludara 64 antitumor activity 64 antitumor 64 therapeutic regimens 64 alkylating agents 63 erlotinib 63 paclitaxel Taxol 63 pegfilgrastim 63 hormonal therapies 63 HER2 positive metastatic breast 63 Doxorubicin 63 azoles 63 nucleoside analogues 63 antisense oligonucleotides 63 Interferon alpha 63 temozolomide 63 intravesical instillation 63 bleomycin 63 alkylating agent 63 immunomodulatory 63 peptide antigens 63 docetaxel Taxotere ® 63 Gefitinib 63 anti angiogenic drugs 63 HDACi 63 immunosuppressive therapies 63 overlapping toxicities 63 hematologic malignancies 63 gamma secretase inhibitors 63 trabectedin 63 dasatinib Sprycel 63 interferon 63 taxol 63 anticancer treatments 63 immunosuppressant 63 protease inhibitors 63 vinorelbine 63 dacarbazine 62 gefitinib Iressa 62 anti leukemic 62 Gleevec resistant 62 gemcitabine Gemzar 62 JAK inhibitors 62 CBLC# 62 Vidofludimus 62 cisplatin chemotherapy 62 interferon IFN 62 Smac mimetic 62 dexamethasone Decadron 62 cetuximab 62 dasatinib 62 gefitinib 62 leucovorin 62 SERMs 62 taxane chemotherapy 62 intravenous bisphosphonates 62 cediranib 62 sorafenib 62 DMARDs 62 ENMD # 62 JAK2 inhibitors 62 vincristine 62 HSP# inhibitor 62 panobinostat 62 rituximab 62 decitabine 62 oncoproteins 62 direct thrombin inhibitors 62 anticancer 62 Gemcitabine 62 seliciclib 62 azacitidine 62 Pemetrexed 62 nucleosides 62 trans retinoic acid ATRA 62 Erlotinib 62 irinotecan chemotherapy 62 gemcitabine chemotherapy 62 Mitoxantrone 62 docetaxel chemotherapy 62 sorafenib Nexavar ® 62 GRN#L 62 milatuzumab 62 microtubule inhibitor 62 PI3K inhibitor 61 metastatic renal cell carcinoma 61 therapies 61 polymerase inhibitors 61 anticancer agent 61 fluorouracil 61 ixabepilone 61 UsiRNAs 61 adjuvant therapy 61 immunotherapies 61 epithelial tumors 61 erlotinib Tarceva 61 kinase inhibitor 61 preclinically 61 microtubule targeting 61 fulvestrant 61 receptor tyrosine kinase inhibitor 61 HGS ETR1 61 selective inhibition 61 proteasome inhibitor bortezomib 61 cytarabine 61 MGd 61 busulfan 61 taxane 61 chemotherapy 61 mapatumumab 61 trans retinoic acid 61 enzyme inhibitors 61 EGF receptor 61 Irinotecan 61 amphotericin B 61 immunomodulating 61 docetaxel Taxotere 61 docetaxel 61 NRTIs 61 lapatinib Tykerb 61 cetuximab Erbitux ® 61 Bortezomib 61 IGF 1R 61 AP# [003] 61 rituximab Rituxan 61 carboplatin paclitaxel 61 radiofrequency ablation RFA 61 EGFR antibodies 61 cilengitide 61 CA4P 61 taxane therapy 61 sunitinib 61 protease inhibitor 61 monoclonal antibody therapies 61 proteasome inhibitor 61 bevacizumab 61 neoadjuvant chemotherapy 61 itraconazole 61 TNF inhibitor 61 talabostat 61 alpha interferon 61 Imprime PGG 61 antiangiogenic 61 fluoropyrimidine 61 apoptotic pathway 61 daunorubicin 61 mAbs 61 vinca alkaloid 61 enzastaurin 61 aminoglycosides 61 cytotoxics 61 liposomal doxorubicin 61 EGFR 61 Bcr Abl inhibitors 61 deacetylase inhibitors 60 TNFa 60 cetuximab Erbitux R 60 immunotoxins 60 superficial bladder cancer 60 bendamustine 60 Preclinical studies suggest 60 temsirolimus 60 PI3K inhibitors 60 Carfilzomib 60 cytostatic 60 ganetespib 60 Panzem R NCD 60 Cloretazine 60 Cytoxan 60 inhibitory effects 60 thalidomide Thalomid 60 small molecule inhibitors 60 HuLuc# 60 Symadex 60 antihypertensive agents 60 malignant pleural mesothelioma 60 DMARDS 60 interferon alpha 60 tipranavir 60 arsenic trioxide 60 depsipeptide 60 microwave hyperthermia 60 conventional chemotherapies 60 VAPRISOL 60 metastatic RCC 60 PKC# 60 carboplatin 60 CLL cells 60 YONDELIS 60 histone deacetylase inhibitors 60 epirubicin 60 OncoVEX GM CSF 60 mitoxantrone 60 GnRH agonists 60 LHRH agonists 60 PARP inhibitor 60 mitomycin 60 Epothilones 60 paclitaxel 60 erythropoietic 60 Doxil ® 60 act synergistically 60 p# inhibitors 60 lupus nephritis 60 histone deacetylase inhibitor 60 lenalidomide dexamethasone 60 thrombopoietin 60 OMP #M# 60 antiviral therapies 60 Sorafenib 60 nucleoside analog 60 HGS# 60 irinotecan 60 albumin bound paclitaxel 60 nephrotoxicity 60 ISTODAX 60 imatinib Gleevec ® 60 azacytidine 60 Vorinostat 60 cytoprotective 60 myeloma cells 60 photosensitizer 60 echinocandins 60 alkylating 60 5 Fluorouracil 60 immune stimulatory 60 anti VEGF 60 biologic therapy 60 tumor cells 60 pegylated liposomal doxorubicin 60 HDAC inhibition 60 Doxil 60 immunotherapy 60 differentiated thyroid 60 methotrexate 59 immunosuppressive 59 antiangiogenic therapy 59 antiangiogenic agents 59 imatinib mesylate 59 echinocandin 59 BRAF inhibitor 59 CD# antibody [001] 59 VDAs 59 trastuzumab Herceptin ® 59 insulin sensitizers 59 antimetabolite 59 vascular disrupting agents 59 adecatumumab 59 chemopreventive agents 59 docetaxel Taxotere R 59 angiogenesis inhibitor 59 Neuradiab 59 DOXIL 59 IFN alpha 59 nucleoside analogue 59 chemoresistance 59 T#I [002] 59 melphalan 59 standard chemotherapy regimen 59 visilizumab 59 AKT inhibitor 59 chemoradiation 59 anti angiogenic 59 trastuzumab Herceptin 59 kinase inhibition 59 heavily pretreated patients 59 endocrine therapies 59 DFMO 59 rHuPH# 59 hepatic metastases 59 SCH # 59 Xanafide 59 raltegravir 59 ganciclovir 59 ISF# 59 humanized antibody 59 LY# [003] 59 EGFR TKIs 59 IMC A# 59 Trastuzumab 59 recurrent NSCLC 59 uric acid lowering 59 beta lactam antibiotics 59 G CSF 59 antineoplastic 59 Fludara ® 59 tumor antigens 59 Azedra 59 alpha interferons 59 BRAF inhibitors 59 photodynamic therapy 59 Hsp# inhibitors 59 axitinib 59 bortezomib Velcade 59 sulfasalazine 59 bevacizumab Avastin R 59 cyclosporin 59 myeloproliferative disorders 59 TNF inhibitors 59 Docetaxel 59 adriamycin 59 gemcitabine cisplatin 59 octreotide 59 tubulin binding 59 myelosuppression 59 myelofibrosis polycythemia vera 59 LHRH antagonists 59 Perifosine 59 L asparaginase 59 intravesical 59 pharmacokinetic interactions 59 interferon alfa 59 PLX# 59 azole 59 hematological cancers 59 BAY #-# 59 humanized monoclonal antibodies 59 immunomodulators 59 VEGF receptor 59 chemotherapy gemcitabine 59 recombinant erythropoietin 59 Rituxan rituximab 59 myeloablative 59 substrates inhibitors 59 BMS # 59 Bevacizumab 59 Herceptin trastuzumab 59 amrubicin 59 antiandrogens 59 chemopreventive agent 59 Bcr Abl mutations 59 potent inhibitors 59 TKI therapy 59 Protease inhibitors 59 topical retinoids 59 Zolinza 59 belinostat 59 radionuclide therapy 59 tigecycline 59 glioma cells 59 mRCC 59 EGFr 59 HCV protease inhibitors 59 Darinaparsin 59 XmAb# 59 PROCHYMAL 59 molecular biomarkers 59 antitumoral 59 pentamidine 59 IFN beta 59 HDAC inhibitor 58 imatinib therapy 58 radiolabeled monoclonal antibody 58 Dasatinib 58 delta isoform 58 dasatinib Sprycel ® 58 pegylated interferons 58 lapatinib 58 Gemzar ® 58 inhibiting tumor 58 immunosuppressive regimens 58 Platinol ® cisplatin 58 azathioprine 58 Taxotere R 58 biodistribution 58 colorectal liver metastases 58 antiproliferative 58 antisense 58 HCV protease 58 endothelin receptor antagonists 58 pancreatic adenocarcinoma 58 interferon alfa 2a 58 neoadjuvant therapy 58 fibrinolytic 58 fluconazole 58 bexarotene 58 novel peptide 58 chemotherapy docetaxel 58 Smac mimetics 58 Th2 cytokines 58 paclitaxel cisplatin 58 Taxotere chemotherapy 58 entinostat 58 geldanamycin 58 Cremophor 58 Tyrima 58 anti angiogenic therapy 58 sirolimus 58 dose cytarabine 58 immune modulator 58 anti proliferative 58 FUSILEV enhances 58 cidofovir 58 nab paclitaxel 58 Chemophase 58 protein kinase inhibitor 58 IAP inhibitor 58 CYT# potent vascular disrupting 58 recurrent glioblastoma multiforme 58 Vidaza ® 58 pegylated interferon alfa 58 imatinib resistant 58 DMARD 58 virotherapy 58 CYP#A# inhibitors 58 Mitomycin C 58 immune modulatory 58 multikinase inhibitor 58 transgene expression 58 immune modulators 58 systemically administered 58 cisplatin carboplatin 58 K ras mutations 58 alefacept 58 chemotherapeutic regimen 58 antitumor effect 58 ritonavir boosted 58 radiolabeled TM# 58 VEGFR2 58 Gleevec imatinib mesylate 58 Taxol ® 58 camptothecin 58 antiinflammatory 58 gemcitabine carboplatin 58 IAP inhibitors 58 nucleoside 58 Taxol paclitaxel 58 receptor antagonists 58 Taxanes 58 Anthracyclines 58 xanthine oxidase inhibitor 58 chemopreventive 58 antifolate 58 poly ADP ribose polymerase 58 DAVANAT 58 corticosteroid therapy 58 anti angiogenic therapies 58 PEGPH# 58 Imatinib 58 small interfering RNA 58 sorafenib tablets 58 anti angiogenic agent 58 doxorubicin HCl 58 resistant ovarian cancer 58 flavopiridol 58 preclinical xenograft models 58 CHOP chemotherapy 58 anti mitotic 58 Tarceva erlotinib 58 histone deacetylase HDAC inhibitors 58 toxicities 58 mutational status 58 tumor vasculature 58 gastrointestinal stromal tumors GIST 58 chemoradiotherapy 58 gamma secretase inhibitor 58 biologic therapies 58 NKT cells 58 pharmacologic 58 oncogenes 58 cytotoxic therapies 58 receptor subtypes 58 Corticosteroids 58 enzyme inhibitor 58 Cloretazine R 58 rituximab Rituxan ® 58 Etoposide 58 antifungal therapy 58 metastatic relapsed 58 temozolomide TMZ 58 Navelbine ® 58 oral antiviral 58 posaconazole 58 SARMs 58 dosing regimens 58 histone deacetylase HDAC inhibitor 58 induce apoptosis 58 retinoid 58 cancer immunotherapies 58 lipid lowering therapies 58 predictive biomarkers 58 Taxotere docetaxel 58 Onconase 58 c MET 58 quinolone 58 monoclonal antibodies 58 HGS ETR1 mapatumumab 58 metastatic colorectal 58 basal cell carcinoma BCC 58 endostatin 58 pyrimethamine 58 Aurora kinase 58 leflunomide 58 tamoxifen Nolvadex ® 58 AEG# 58 brostallicin 58 tumorigenic 58 cisplatin gemcitabine 58 Xcytrin 58 TELINTRA 58 Elotuzumab 58 nanomolar 58 histologies 58 Hsp# inhibition 58 denileukin diftitox 58 EGFR inhibition 58 Squalamine 58 aminoglycoside 58 CCR2 58 sulindac 58 panitumumab Vectibix 58 leukemia AML 58 FOLFIRINOX 58 malignancies 57 proteases 57 signal transduction inhibitor 57 liposomal formulation 57 favorable pharmacokinetic profile 57 MDM2 57 selective inhibitors 57 Interferon alfa 57 synthetic retinoid 57 MyVax R 57 galiximab 57 pimozide 57 pro apoptotic 57 pro angiogenic 57 nilotinib Tasigna ® 57 refractory NSCLC 57 tumor subtypes 57 enveloped viruses 57 olaparib 57 metastatic melanoma 57 ALK inhibitor 57 CYC# 57 lytic 57 Paraplatin ® 57 Glucocorticoids 57 liposomal 57 radiation chemoradiation 57 Clofarabine 57 demonstrated antitumor activity 57 Tamibarotene 57 siRNAs 57 APTIVUS r 57 trastuzumab Herceptin R 57 NF kB pathway 57 histone deacetylases 57 BCR ABL 57 LHRH analogues 57 immune modulating 57 leukemia CLL 57 IFNs 57 Blinatumomab 57 Pegasys ® 57 synthetic analogues 57 phosphate S1P 57 immunosuppressive drugs 57 adjuvant therapies 57 tyrosine kinase inhibitor TKI 57 hyperthermia therapy 57 FK# 57 antibody fragment 57 Nanobodies 57 oncolytic virus 57 chemotherapy regimen 57 metastatic tumors 57 somatostatin analogue 57 Pertuzumab 57 EFAPROXYN 57 caspofungin 57 glucocorticoids 57 receptor inhibitor 57 Velcade bortezomib 57 Omacetaxine mepesuccinate 57 pomalidomide 57 signaling cascades 57 IMGN# 57 Pegylated Interferon 57 Rituximab 57 neurotrophic 57 Platinol 57 palliative radiotherapy 57 pemetrexed 57 quinolones 57 anti CD3 57 small molecule tyrosine 57 Nexavar ® 57 siRNA therapeutics 57 cisplatin resistant 57 anti fibrotic 57 orally bioavailable 57 topical corticosteroids 57 targeting CD# 57 obatoclax 57 TNF alpha inhibitors 57 pDCs 57 pan HDAC inhibitor 57 retinoids 57 bone marrow suppression 57 bicalutamide 57 nutlin 3a 57 HER2 receptor 57 CANCIDAS 57 endoxifen 57 inhibitor RG# 57 EGFR HER2 57 Vandetanib 57 angiogenesis inhibitors 57 Seliciclib 57 Hycamtin 57 corticosteroid dexamethasone 57 non nucleoside 57 Neulasta ® 57 amikacin 57 macrolide antibiotics 57 Abatacept 57 Combination therapy 57 hematopoietic cells 57 N acetylcysteine 57 asparaginase 57 beta agonists 57 Vidaza azacitidine 57 fluoroquinolone antibiotic 57 tumor xenograft models 57 imatinib resistance 57 Carboplatin 57 Voreloxin 57 metastatic kidney 57 oncolytic 57 radiolabeled antibodies 57 EGFR inhibitor 57 ansamycin 57 EGFRvIII 57 immunomodulatory therapy 57 chronic lymphocytic leukemia CLL 57 FOLFOX4 57 oral prodrug 57 MAbs 57 ceftriaxone 57 zoledronic acid 57 monoclonal 57 pyrimidines 57 antithrombotic 57 disease modifying antirheumatic 57 Erbitux cetuximab 57 hepatoma 57 neratinib 57 CDK inhibitor 57 selective kinase inhibitor 57 TNF antagonists 57 dosage regimens 57 pharmacological approaches 57 androgen deprivation 57 Paraplatin ® carboplatin 57 insulin sensitizing 57 chlorambucil 57 indinavir 57 CD# expressing 57 intravenous cyclophosphamide 57 potent antiproliferative 57 relapsed SCLC 57 allopurinol 57 hedgehog pathway 57 Ontak 57 metastatic cancers 57 proliferative disorders 57 FOLFOX chemotherapy 57 OncoVEX 57 Radiofrequency ablation 57 #ME# 57 antifungal agents 57 MetMAb 57 antimitotic 57 calcitriol 57 breast cancer subtypes 57 targeted antifolate 57 prostanoid 57 M2 subunit 57 Monoclonal antibodies 57 recurrent ovarian cancer 57 Skp2 57 TLR agonists 57 EpCAM 57 vasodilators 57 bone metastasis 57 soluble receptor 57 Targretin 57 metastatic malignant 57 PGE2 57 cytotoxic effects 57 Telintra 57 topoisomerase 57 external beam radiotherapy 57 effector cells 57 chemotherapeutic treatments 57 NXL# 57 disease modifying 57 familial amyloidotic polyneuropathy FAP 57 systemic antifungal 57 mitochondrial toxicity 57 interleukins 57 antiandrogen 57 mesothelin 57 serologically active systemic lupus 57 grade gliomas 57 Pralatrexate 57 siRNA molecules 57 dacarbazine DTIC 57 cardiac toxicity 57 VEGF receptors 57 antihormonal 57 HIF PH inhibitors 57 Traficet EN 57 indomethacin 57 dexrazoxane 57 renal toxicity 57 NF kappaB activation 57 Anticalins ® 57 meropenem 57 Fludarabine 57 Amplimexon 57 Sym# 57 Aplidin 57 HMG CoA reductase inhibitors 57 humanized anti 57 ERK1 2 57 LEP ETU 57 antidiabetic 57 CD# antibodies 57 liposome encapsulated 57 beta adrenergic 57 viral vectors 57 relapsed refractory 57 irinotecan doxorubicin oxaliplatin paclitaxel 57 VIDAZA 57 neuroendocrine tumors 56 effector function 56 TTF Therapy 56 mupirocin 56 KIT mutations 56 interferon alfa 2b 56 Ceflatonin 56 idraparinux 56 5 FU leucovorin 56 antitumor efficacy 56 hematological malignancies 56 pancreatic NET 56 oblimersen 56 EGFR mutations 56 multi kinase inhibitor 56 autoantigens 56 drug zotarolimus 56 liver metastases 56 glioblastoma cells 56 lymphomas 56 administered orally 56 stable nucleic acid 56 colon carcinoma 56 sunitinib malate 56 DNA methyltransferases 56 molecularly targeted therapies 56 interferon beta 56 DAPT 56 antisense drugs 56 E#F# 56 IGF IR 56 CLORETAZINE TM VNP#M 56 PDE4 inhibitors 56 fondaparinux 56 vandetanib 56 peritoneal carcinomatosis 56 antisense compounds 56 marketed EGFR 56 intravenously administered 56 WT1 56 antiangiogenesis 56 Avastin bevacizumab 56 metastatic lesions 56 hepatocytes 56 estramustine 56 fibrotic disease 56 antimetastatic 56 thrombolytic agents 56 antiplatelet therapies 56 glioblastoma multiforme GBM 56 chemosensitivity 56 metaglidasen 56 NEUGENE 56 Raltegravir 56 OHR/AVR# 56 infliximab Remicade 56 protein kinase inhibitors 56 radezolid 56 adoptive immunotherapy 56 CYP #A# 56 antisense RNA 56 corticosteroids 56 calcitonin 56 androgen receptor AR 56 paricalcitol 56 TRV# [001] 56 estrogen receptor beta 56 voreloxin 56 pegylated interferon alfa 2a 56 Temozolomide 56 neuroendocrine cancers 56 Everolimus 56 cell lysis 56 PDGF receptor 56 immunomodulatory effects 56 subcutaneous formulation 56 malignant growths 56 bortezomib Velcade R 56 MAb 56 AMN# [001] 56 Surgical resection 56 immune suppressing 56 oncology indications 56 Celecoxib 56 TLR9 agonists 56 EOquin 56 papillary renal cell carcinoma 56 Akt activation 56 ESBA# 56 topical formulations 56 PPARgamma 56 mertansine 56 Lenocta 56 selectively inhibited 56 leukemic stem cells 56 monotherapy 56 antiproliferative effects 56 radiolabeled 56 HbF 56 PI3K Akt 56 Cetuximab 56 thyroid hormone receptor 56 novel anticancer 56 anti tubercular 56 tipifarnib 56 Taxotere ® 56 Gleevec imatinib 56 granisetron 56 antitumor effects 56 iron chelators 56 HDAC 56 lamivudine 56 parthenolide 56 pharmacodynamic markers 56 OXi# 56 chemoresistant 56 Bleomycin 56 Oxaliplatin 56 Bisphosphonates 56 Neoadjuvant 56 adenoviral 56 Orally administered 56 Tumor Necrosis Factor 56 CTLA 4 56 GP IIb IIIa inhibitors 56 Src inhibitors 56 Hedgehog signaling pathway 56 factor G CSF 56 systemic toxicity 56 PREZISTA r 56 ibritumomab tiuxetan 56 Aromatase inhibitors 56 celecoxib 56 myeloproliferative diseases 56 ERBB2 56 angiotensin receptor blocker ARB 56 GBM tumors 56 hormone LHRH antagonist 56 sunitinib Sutent ® 56 metastatic colorectal cancer 56 carcinomas 56 fludarabine 56 orally dosed 56 interleukin IL -# 56 mutated KRAS gene 56 AEGR 56 Lenalidomide 56 vinblastine 56 TLR8 agonist 56 pharmacokinetic properties 56 Teriflunomide 56 Xeloda capecitabine 56 immunoconjugate 56 Zoledronic acid 56 bactericidal 56 paclitaxel Taxol ® 56 5-FU/LV 56 FOLFIRI 56 effector T 56 potent cytotoxic 56 treatment regimens 56 lymphoid malignancies 56 NKG2D 56 NovaBay Aganocide compounds 56 dosing schedules 56 tumor hypoxia 56 Vaprisol 56 ON #.Na 56 IGFBP 3 56 Vectibix monotherapy 56 #I TM# 56 forskolin 56 concurrent chemoradiation 56 JAK3 56 OPAXIO 56 antifolates 56 platelet inhibitor 56 nucleoside reverse transcriptase inhibitor 56 GAP #B# 56 isoproterenol 56 photosensitizers 56 C. difficile toxins 56 metastatic 56 neurotrophic factors 56 TNF α 56 cetuximab Erbitux 56 LNP formulations 56 humanised monoclonal antibody 56 Gliadel Wafer 56 T DM1 56 Reolysin 56 nilotinib